Eli Lilly and Co
SIX:LLY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Eli Lilly and Co
SIX:LLY
|
US |
|
E
|
Else Nutrition Holdings Inc
TSX:BABY
|
IL |
|
Transmedics Group Inc
NASDAQ:TMDX
|
US |
|
C
|
Chengdu Huasun Technology Group Co Ltd
SZSE:000790
|
CN |
Revenue Breakdown
Breakdown by Geography
Eli Lilly and Co
|
Total Revenue:
65.2B
USD
|
|
United States:
30.4B
USD
|
|
Outside United States:
14.7B
USD
|
|
Europe:
6.9B
USD
|
|
Rest Of World:
4.3B
USD
|
|
Japan:
1.8B
USD
|
|
China:
1.7B
USD
|
Breakdown by Segments
Eli Lilly and Co
|
Total Revenue:
65.2B
USD
|
|
Reportable Segment:
45B
USD
|
|
Net Product Revenue:
40.7B
USD
|
|
Cardiometabolic Health:
7.7B
USD
|
|
Collaboration And Other Revenue:
4.3B
USD
|
|
Oncology:
3.7B
USD
|
|
Immunology:
1.9B
USD
|
|
Olumiant:
957.4m
USD
|
|
Neuroscience:
693.5m
USD
|
|
Basaglar®:
676.9m
USD
|
|
Other:
651.6m
USD
|
|
Tyvyt:
526m
USD
|
|
Jardiance:
300m
USD
|